Evolus, Inc. (EOLS)Healthcare | Drug Manufacturers - Specialty & Generic | Newport Beach, United States | NasdaqGM
6.52 USD
-0.09
(-1.362%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:39 a.m. EDT
The investment case for Evolus is currently broken by deteriorating fundamentals and a lack of shareholder returns. The company is generating negative free cash flow and operating losses, while its stock has suffered a catastrophic -65% decline over the last seven years. Although analysts maintain a 'strong buy' rating with a target price significantly higher than the current level, this optimism appears disconnected from the reality of a shrinking balance sheet and eroding book value. The absence of any dividend history confirms that management is not returning capital to shareholders. Furthermore, the options market is screaming caution; the heavy concentration of put open interest at deep strikes indicates that retail and institutional traders are betting on further downside, not a recovery. Until the company demonstrates a path to profitability and stops burning cash, this remains a speculative trap rather than a turnaround opportunity. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.169391 |
| AutoETS | 0.169395 |
| MSTL | 0.174382 |
| AutoTheta | 0.204222 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 2.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.865 |
| Excess Kurtosis | -0.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 4.654 |
| Market Cap | 429,372,992 |
| Forward P/E | 27.17 |
| Beta | 1.32 |
| Profit Margins | -14.39% |
| Website | https://www.evolus.com |
As of July 11, 2026, 2:39 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes at 2.5 and 5.0) compared to negligible call volume. While there is some speculative call activity at the 10.0 strike, the overwhelming capital allocation is defensive, suggesting a fear of further decline rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.2966559 |
| Address1 | 520 Newport Center Drive |
| Address2 | Suite 1200 |
| All Time High | 39.5 |
| All Time Low | 2.85 |
| Ask | 8.14 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 776,830 |
| Average Daily Volume3 Month | 844,924 |
| Average Volume | 844,924 |
| Average Volume10Days | 776,830 |
| Beta | 1.32 |
| Bid | 4.74 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | -0.437 |
| City | Newport Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.52 |
| Current Ratio | 2.042 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.61 |
| Day Low | 6.29 |
| Display Name | Evolus |
| Earnings Call Timestamp End | 1,777,926,600 |
| Earnings Call Timestamp Start | 1,777,926,600 |
| Earnings Timestamp | 1,777,924,800 |
| Earnings Timestamp End | 1,785,873,600 |
| Earnings Timestamp Start | 1,785,873,600 |
| Ebitda | -23,152,000 |
| Ebitda Margins | -0.07672 |
| Enterprise To Ebitda | -23.518 |
| Enterprise To Revenue | 1.804 |
| Enterprise Value | 544,483,968 |
| Eps Current Year | -0.094 |
| Eps Forward | 0.24 |
| Eps Trailing Twelve Months | -0.66 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.5424 |
| Fifty Day Average Change | -0.022399902 |
| Fifty Day Average Change Percent | -0.003423805 |
| Fifty Two Week Change Percent | -29.665588 |
| Fifty Two Week High | 10.2 |
| Fifty Two Week High Change | -3.6799998 |
| Fifty Two Week High Change Percent | -0.3607843 |
| Fifty Two Week Low | 3.86 |
| Fifty Two Week Low Change | 2.66 |
| Fifty Two Week Low Change Percent | 0.6891192 |
| Fifty Two Week Range | 3.86 - 10.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,518,100,200,000 |
| Float Shares | 50,043,025 |
| Forward Eps | 0.24 |
| Forward P E | 27.166668 |
| Free Cashflow | -23,226,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 350 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.66055 |
| Gross Profits | 199,348,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14682999 |
| Held Percent Institutions | 0.70352 |
| Implied Shares Outstanding | 65,854,751 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California. |
| Long Name | Evolus, Inc. |
| Market | us_market |
| Market Cap | 429,372,992 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_229087176 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -43,423,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 428,714,429 |
| Number Of Analyst Opinions | 6 |
| Open | 6.61 |
| Operating Cashflow | -36,585,000 |
| Operating Margins | -0.09382 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 949 284 4555 |
| Pre Market Change | 0.13870001 |
| Pre Market Change Percent | 2.1273007 |
| Pre Market Price | 6.6587 |
| Pre Market Time | 1,784,026,062 |
| Previous Close | 6.61 |
| Price Eps Current Year | -69.3617 |
| Price Hint | 2 |
| Price To Book | -14.919909 |
| Price To Sales Trailing12 Months | 1.4227494 |
| Profit Margins | -0.14388 |
| Quick Ratio | 1.5 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | -0.0900002 |
| Regular Market Change Percent | -1.36158 |
| Regular Market Day High | 6.61 |
| Regular Market Day Low | 6.29 |
| Regular Market Day Range | 6.29 - 6.61 |
| Regular Market Open | 6.61 |
| Regular Market Previous Close | 6.61 |
| Regular Market Price | 6.52 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,302,114 |
| Return On Assets | -0.090550005 |
| Revenue Growth | 0.067 |
| Revenue Per Share | 4.654 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 65,854,751 |
| Shares Percent Shares Out | 0.091400005 |
| Shares Short | 6,018,141 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 6,059,626 |
| Short Name | Evolus, Inc. Common Stock |
| Short Percent Of Float | 0.0925 |
| Short Ratio | 7.66 |
| Source Interval | 15 |
| State | CA |
| Symbol | EOLS |
| Target High Price | 20.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 14.66667 |
| Target Median Price | 14.0 |
| Total Cash | 49,792,000 |
| Total Cash Per Share | 0.756 |
| Total Debt | 164,903,008 |
| Total Revenue | 301,791,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.66 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.89935 |
| Two Hundred Day Average Change | 0.6206498 |
| Two Hundred Day Average Change Percent | 0.105206475 |
| Type Disp | Equity |
| Volume | 1,302,114 |
| Website | https://www.evolus.com |
| Zip | 92,660 |